期刊
JOURNAL OF NUCLEAR MEDICINE
卷 49, 期 1, 页码 129-134出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.106.038836
关键词
CE-355621; c-Met inhibitor; F-18-FDG; microPET; drug evaluation; therapy response
资金
- NATIONAL CANCER INSTITUTE [R24CA092862] Funding Source: NIH RePORTER
- NCI NIH HHS [R24 CA092862, R24CA92862] Funding Source: Medline
The purpose of this study was to evaluate the efficacy of CE-355621, a novel antibody against c-Met, in a subcutaneous U87 MG xenograft mouse model using F-18-FDG small-animal PET. Methods: CE-355621 or control vehicle was administered intraperitoneally into nude mice (drug-treated group, n = 12; control group, n = 14) with U87 MG subcutaneous tumor xenografts. Drug efficacy was evaluated over 2 wk using F-18-FDG small-animal PET and compared with tumor volume growth curves. Results:The maximum %ID/g (percentage injected dose per gram of tissue) of F-18-FDG accumulation in mice treated with CE-355621 remained essentially unchanged over 2 wk, whereas the %ID/g of the control tumors increased 66% compared with the baseline. Significant inhibition of F-18-FDG accumulation was seen 3 d after drug treatment, which was earlier than the inhibition of tumor volume growth seen at 7 d after drug treatment. Conclusion: CE-355621 is an efficacious novel antineoplastic chemotherapeutic agent that inhibits F-18-FDG accumulation earlier than tumor volume changes in a mouse xenograft model. These results support the use of F-18-FDG PET to assess early tumor response for CE-355621.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据